Biomarkers in Clinical Drug Development (Drugs and the Pharmaceutical Sciences)

---

Standards of evidence used in drug development should also be applied to biomarker development. This is a very important point.

The National Biomarker Development Alliance, of which I am a member, is dedicated to establishing standards that can provide guidelines for academic investigators, journals, and other participants in the publication process to enhance the validity of published biomarker reports. Other groups are also trying to develop guidelines for biomarker discovery protocols, including the one led by John Quackenbush.

We believe that strengthening the analytical validation of the biomarker assays on the front end, and strengthening the data analysis specifics on the back end, will greatly enhance the accuracy of reported biomarker findings in the literature. In order for academic work to gain more traction, greater attention must be paid to biomarker validation and qualification. Because of the plethora of opportunities, it will be important to identify priority areas on the basis of high unmet medical need and lack of clinically tractable endpoints.

Development of a framework for an objective, cost—benefit model to evaluate and prioritize biomarkers to pursue for qualification would be helpful. It would then be important to incentivize academia to develop focused efforts to provide the level of evidence necessary to qualify biomarkers. This issue may likely represent poorly designed studies and a lack of application of rigorous assay qualification standards.

Biomarkers in Clinical Drug Development (Drugs and the by John Bloom,Richard A. Dean

Ensuring that grant-funding agencies and journals demand and facilitate clear descriptions of the analytical validation of assays and sample collection procedures will go a long way to addressing these concerns. What is the main driver for the codevelopment of drugs and companion diagnostics? How do you envision companion diagnostics affecting the practice of laboratory medicine? As our knowledge of biology and technology advances, there will be many situations in which a specific drug will have a favorable benefit—risk profile in only a defined subset of patients with a particular disease.

That is, patients will be selected on the basis of who is most likely to show clinical improvement or not experience serious adverse events. Companion diagnostics will be critical for identifying these subsets, and codevelopment of the drug and diagnostic is generally the most effective path.

Post navigation

Details regarding testing, clinical trial design, regulatory, and commercialization aspects of companion diagnostics are still evolving. Because companion diagnostics play an increasing role, clinical laboratories will need to accommodate new tests and their corresponding platforms. The main driver is personalized or stratified medicine. I prefer the term stratified medicine because what we are really hoping to do, by combining a drug with a diagnostic, is to simply increase the likelihood that the patient will respond favorably to administered therapeutics on the basis of the molecular details of their disease.

Companion diagnostics is almost certain to become a standard practice of laboratory medicine. Next generation sequencing NGS and whole genome sequencing, once stabilized, will greatly impact the field of codiagnostics. The primary driver for companion diagnostics is to enable safe and effective innovative therapies in segmented patient populations, whereas unselected populations would not enjoy the same benefits. Companion diagnostics should become an increasingly important component of the practice of laboratory medicine.

Diagnostics codeveloped with therapeutics are often although not exclusively used to measure a biomarker that can identify the patient population most likely to benefit or potentially be harmed from the therapeutic intervention. Being able to identify the patient population who can gain the most benefit from a therapy is the primary driver. The impact on laboratory medicine can vary depending on the platform upon which the biomarker is measured and whether assays for the measurement of that biomarker already exist as a laboratory-developed test LDT.

A further complication would occur if another companion diagnostic existed to measure the same biomarker, but on a different platform and with a different cutoff value. There is currently a great effort directed at the qualification of biomarkers for use in clinical trials, such as the different initiatives from the C-Path Institute of the NIH.

How do you envision these efforts enabling clinical trials in the future? Biomarkers that are well qualified will enhance their value to predict clinical response and, hence, increase their clinical utility. Well-qualified biomarkers can be used to identify patient responses to medications in trials in which the length of therapy or the number of patients is not sufficient to show a statistically significant change in a clinical endpoint.

These efforts can provide transversal benefits across multiple programs and therapeutic areas. Clinical qualification of genomic, proteomic, metabolomic, and imaging technologies, as well as optimal clinical trial design, will have major impacts on enabling clinical trial data to be most effectively used both for later-stage trials as well as for decision-making in earlier clinical studies. Qualified biomarkers in priority areas will drive faster and more effective clinical trials, resulting in better and innovative therapies. Qualifications resulting in surrogate endpoints, which satisfy regulatory requirements, as well as companion diagnostics, will drive approval of new therapies.

The qualification of biomarkers for a specific context of use that allows more rapid evaluation of the benefit of a particular therapy will have a significant impact on drug development. Qualification of surrogate endpoints a biomarker that substitutes for a clinical endpoint will obviously positively impact drug development.

In this issue

Pharmacogenomics has been helpful in understanding the difference in metabolism of certain drugs, such as warfarin. Pharmacogenomics will have a greater focus on the identification of patient subsets that show differential response to a drug e. There is a need to recognize and understand outliers in responses. Pharmacogenomics is experiencing an increasing role in patient selection as evidenced by the inclusion in drug labels for required or recommended use, resulting in a large number of personalized medicine therapies.

Please accept our apologies for any inconvenience this may cause. Add to Wish List. Toggle navigation Additional Book Information. Description Table of Contents Reviews.

BOOK SERIES

Table of Contents Biomarkers in clinical drug development - definitions and disciplines, John C. Bloom; the clinical laboratory and collection of biomarker data, Gordon F.

Kapke and Robert A. Dean; using imaging biomarkers to demonstrate efficacy in clinical trials - trends and challenges, Charles G.

Download Biomarkers in Clinical Drug Development (Drugs and the by John Bloom, Richard A. Dean PDF

Peterfy and Barbara Maley; markers for cardiac repolarization and risk assessment, William J. Groh and Gregory D. Sides; development and application of interspecies biomarkers in nonclinical safety evaluations, Frank D. Masking the talents wanted for pharmaceutical care in a patient-centered pharmacy environment, scientific talents for Pharmacists: A Patient-Focused technique, third variation describes basic abilities akin to conversation, actual evaluate, and laboratory and diagnostic details, in addition to sufferer case presentation, healing making plans, and tracking of drug consumption.

Introduction to Textile Fibres. Advent to fabric Fibres offers invaluable info for newcomers. In , the e-book received the coveted "Best Technical booklet in cloth" — Century generators Award via fabric organization India. Moreover, the potential role that imaging could play in clinical trials is the same role it currently plays in clinical practice, namely patient selection diagnosis and staging , monitoring disease progression and treatment response, and assessing complications of therapy. By providing realtime feedback through the reporting process, the clinical laboratory becomes an essential communication link in successful biomarker data delivery.

Delay in transit can result in specimens being received in a degraded condition.

• The House Of Jack: Tales from an illegal BDSM sex club
• The Pitfalls of Speculation
• Overview of Immigration Issues in the 112th Congress
• Stitch of Courage: A Womans Fight of Freedom (Trail of Thread Series Book 3)
• A Maverick Investors Guidebook